Indicator type;Main activity, secondary activity or tool required for...;Total
Companies carrying out R&D in Biotechnology;Total;1,376
Companies carrying out R&D in Biotechnology;Main;711
Companies carrying out R&D in Biotechnology;Secondary;270
Companies carrying out R&D in Biotechnology;Tool required;395
% Companies by type of biotechnology used: Genetic Code;Total;31.4
% Companies by type of biotechnology used: Genetic Code;Main;37.1
% Companies by type of biotechnology used: Genetic Code;Secondary;28.5
% Companies by type of biotechnology used: Genetic Code;Tool required;23.3
% Companies by type of biotechnology used: Functional Units;Total;43.7
% Companies by type of biotechnology used: Functional Units;Main;50.2
% Companies by type of biotechnology used: Functional Units;Secondary;38.9
% Companies by type of biotechnology used: Functional Units;Tool required;35.3
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Total;22.8
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Main;26.3
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Secondary;22.6
% Companies by type of biotechnology used: Cell and Tissue Culture and Engineering;Tool required;16.8
% Companies by type of biotechnology used: Bioprocesses;Total;48.3
% Companies by type of biotechnology used: Bioprocesses;Main;38.7
% Companies by type of biotechnology used: Bioprocesses;Secondary;59.0
% Companies by type of biotechnology used: Bioprocesses;Tool required;58.2
% Companies by type of biotechnology used: Subcellular Organisms;Total;7.9
% Companies by type of biotechnology used: Subcellular Organisms;Main;10.6
% Companies by type of biotechnology used: Subcellular Organisms;Secondary;6.0
% Companies by type of biotechnology used: Subcellular Organisms;Tool required;4.2
% Companies by type of biotechnology used: Bioinformatics;Total;27.1
% Companies by type of biotechnology used: Bioinformatics;Main;34.0
% Companies by type of biotechnology used: Bioinformatics;Secondary;21.5
% Companies by type of biotechnology used: Bioinformatics;Tool required;18.7
% Companies by type of biotechnology used: Nanobiotechnology;Total;11.2
% Companies by type of biotechnology used: Nanobiotechnology;Main;14.5
% Companies by type of biotechnology used: Nanobiotechnology;Secondary;10.0
% Companies by type of biotechnology used: Nanobiotechnology;Tool required;6.2
% Companies by type of biotechnology used: Other;Total;17.6
% Companies by type of biotechnology used: Other;Main;19.2
% Companies by type of biotechnology used: Other;Secondary;17.3
% Companies by type of biotechnology used: Other;Tool required;15.0
% Companies by final application areas of biotechnology use: Human Health;Total;48.0
% Companies by final application areas of biotechnology use: Human Health;Main;64.5
% Companies by final application areas of biotechnology use: Human Health;Secondary;33.7
% Companies by final application areas of biotechnology use: Human Health;Tool required;28.1
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Total;16.9
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Main;17.2
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Secondary;18.2
% Companies by final application areas of biotechnology use: Animal Health and Aquaculture;Tool required;15.3
% Companies by final application areas of biotechnology use: Food Products;Total;29.4
% Companies by final application areas of biotechnology use: Food Products;Main;20.1
% Companies by final application areas of biotechnology use: Food Products;Secondary;34.5
% Companies by final application areas of biotechnology use: Food Products;Tool required;42.7
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Total;25.7
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Main;21.8
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Secondary;31.3
% Companies by final application areas of biotechnology use: Agriculture and Forestry;Tool required;28.9
% Companies by final application areas of biotechnology use: Environment;Total;18.0
% Companies by final application areas of biotechnology use: Environment;Main;16.2
% Companies by final application areas of biotechnology use: Environment;Secondary;24.6
% Companies by final application areas of biotechnology use: Environment;Tool required;16.8
% Companies by final application areas of biotechnology use: Industry;Total;13.0
% Companies by final application areas of biotechnology use: Industry;Main;11.7
% Companies by final application areas of biotechnology use: Industry;Secondary;17.2
% Companies by final application areas of biotechnology use: Industry;Tool required;12.6
R&D personnel in Biotechnology (PP);Total;17,257
R&D personnel in Biotechnology (PP);Main;9,048
R&D personnel in Biotechnology (PP);Secondary;4,028
R&D personnel in Biotechnology (PP);Tool required;4,180
R&D personnel in Biotechnology (PP): Research personnel;Total;9,195
R&D personnel in Biotechnology (PP): Research personnel;Main;5,201
R&D personnel in Biotechnology (PP): Research personnel;Secondary;2,189
R&D personnel in Biotechnology (PP): Research personnel;Tool required;1,806
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Total;8,061
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Main;3,847
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Secondary;1,840
R&D personnel in Biotechnology (PP): Technical and auxiliary personnel;Tool required;2,375
R&D personnel in Biotechnology (PP). Women;Total;9,980
R&D personnel in Biotechnology (PP). Women;Main;5,508
R&D personnel in Biotechnology (PP). Women;Secondary;2,308
R&D personnel in Biotechnology (PP). Women;Tool required;2,164
R&D personnel in Biotechnology (PP). Women: Research personnel;Total;5,222
R&D personnel in Biotechnology (PP). Women: Research personnel;Main;3,049
R&D personnel in Biotechnology (PP). Women: Research personnel;Secondary;1,239
R&D personnel in Biotechnology (PP). Women: Research personnel;Tool required;934
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Total;4,758
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Main;2,458
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Secondary;1,069
R&D personnel in Biotechnology (PP). Women: Technical and auxiliary personnel;Tool required;1,231
R&D personnel in Biotechnology (FTE);Total;12,883.4
R&D personnel in Biotechnology (FTE);Main;7,145.1
R&D personnel in Biotechnology (FTE);Secondary;2,868.7
R&D personnel in Biotechnology (FTE);Tool required;2,869.6
R&D personnel in Biotechnology (FTE): Research personnel;Total;7,103.2
R&D personnel in Biotechnology (FTE): Research personnel;Main;4,146.1
R&D personnel in Biotechnology (FTE): Research personnel;Secondary;1,664.6
R&D personnel in Biotechnology (FTE): Research personnel;Tool required;1,292.5
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Total;5,780.2
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Main;2,999.0
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Secondary;1,204.1
R&D personnel in Biotechnology (FTE): Technical and auxiliary personnel;Tool required;1,577.1
R&D personnel in Biotechnology (FTE). Women;Total;7,600.6
R&D personnel in Biotechnology (FTE). Women;Main;4,390.4
R&D personnel in Biotechnology (FTE). Women;Secondary;1,697.6
R&D personnel in Biotechnology (FTE). Women;Tool required;1,512.6
R&D personnel in Biotechnology (FTE). Women: Research personnel;Total;4,057.0
R&D personnel in Biotechnology (FTE). Women: Research personnel;Main;2,442.0
R&D personnel in Biotechnology (FTE). Women: Research personnel;Secondary;931.4
R&D personnel in Biotechnology (FTE). Women: Research personnel;Tool required;683.6
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Total;3,543.7
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Main;1,948.5
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Secondary;766.2
R&D personnel in Biotechnology (FTE). Women: Technical and auxiliary personnel;Tool required;829.0
Expenditure on internal R&D in Biotechnology (thousands of euros);Total;1,283,346
Expenditure on internal R&D in Biotechnology (thousands of euros);Main;793,871
Expenditure on internal R&D in Biotechnology (thousands of euros);Secondary;225,886
Expenditure on internal R&D in Biotechnology (thousands of euros);Tool required;263,589
1) By type of expenditure: Current expenditure;Total;1,180,187
1) By type of expenditure: Current expenditure;Main;730,162
1) By type of expenditure: Current expenditure;Secondary;206,423
1) By type of expenditure: Current expenditure;Tool required;243,601
1.1) Labour expenditure of research personnel;Total;372,421
1.1) Labour expenditure of research personnel;Main;220,559
1.1) Labour expenditure of research personnel;Secondary;79,909
1.1) Labour expenditure of research personnel;Tool required;71,953
1.2) Labour expenditure of technical and auxiliary personnel;Total;229,734
1.2) Labour expenditure of technical and auxiliary personnel;Main;122,582
1.2) Labour expenditure of technical and auxiliary personnel;Secondary;46,028
1.2) Labour expenditure of technical and auxiliary personnel;Tool required;61,124
1.3) Other current expenditure;Total;578,032
1.3) Other current expenditure;Main;387,021
1.3) Other current expenditure;Secondary;80,486
1.3) Other current expenditure;Tool required;110,525
2) By type of expenditure: Capital expenditure;Total;103,159
2) By type of expenditure: Capital expenditure;Main;63,708
2) By type of expenditure: Capital expenditure;Secondary;19,463
2) By type of expenditure: Capital expenditure;Tool required;19,988
2.1) Land and buildings;Total;10,889
2.1) Land and buildings;Main;6,242
2.1) Land and buildings;Secondary;1,295
2.1) Land and buildings;Tool required;3,353
2.2) Equipment and tools;Total;59,204
2.2) Equipment and tools;Main;32,289
2.2) Equipment and tools;Secondary;13,987
2.2) Equipment and tools;Tool required;12,928
2.3) Acquisition of specific R&D software;Total;5,623
2.3) Acquisition of specific R&D software;Main;4,542
2.3) Acquisition of specific R&D software;Secondary;423
2.3) Acquisition of specific R&D software;Tool required;659
2.4) Other R&D-specific IP products;Total;27,442
2.4) Other R&D-specific IP products;Main;20,636
2.4) Other R&D-specific IP products;Secondary;3,758
2.4) Other R&D-specific IP products;Tool required;3,049
1.1) By origin of funds: Own funds;Total;887,527
1.1) By origin of funds: Own funds;Main;533,621
1.1) By origin of funds: Own funds;Secondary;160,796
1.1) By origin of funds: Own funds;Tool required;193,110
1.2) By origin of funds: Funds from the Business sector;Total;143,903
1.2) By origin of funds: Funds from the Business sector;Main;105,847
1.2) By origin of funds: Funds from the Business sector;Secondary;15,390
1.2) By origin of funds: Funds from the Business sector;Tool required;22,666
1.3) By origin of funds: Funds from the Public Administration sector;Total;126,546
1.3) By origin of funds: Funds from the Public Administration sector;Main;77,642
1.3) By origin of funds: Funds from the Public Administration sector;Secondary;25,443
1.3) By origin of funds: Funds from the Public Administration sector;Tool required;23,461
1.4) By origin of funds: Funds from the Higher Education sector;Total;94
1.4) By origin of funds: Funds from the Higher Education sector;Main;76
1.4) By origin of funds: Funds from the Higher Education sector;Secondary;0
1.4) By origin of funds: Funds from the Higher Education sector;Tool required;18
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Total;12,623
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Main;11,461
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Secondary;99
1.5) By origin of funds: Funds from the Private Non-Profit Institutions sector;Tool required;1,063
1.6) By origin of funds: Funds from the rest of the world;Total;112,652
1.6) By origin of funds: Funds from the rest of the world;Main;65,223
1.6) By origin of funds: Funds from the rest of the world;Secondary;24,158
1.6) By origin of funds: Funds from the rest of the world;Tool required;23,271
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Total;137,432
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Main;118,571
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Secondary;11,344
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros);Tool required;7,517
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Total;88,127
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Main;73,357
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Secondary;8,570
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In Spain;Tool required;6,200
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Total;49,305
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Main;45,214
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Secondary;2,774
Purchase of R&D services (external R&D) in Biotechnology (thousands of euros): In the rest of the world;Tool required;1,318
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Total;43.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Main;52.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Secondary;38.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to capital;Tool required;32.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Total;16.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Main;15.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Secondary;21.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to technology/information;Tool required;14.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Total;23.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Main;25.0
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Secondary;21.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Access to human resources;Tool required;22.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Total;14.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Main;14.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Secondary;15.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Disconnection from the value chain;Tool required;13.9
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Total;18.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Main;20.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Secondary;17.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of access to international markets;Tool required;14.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Total;19.6
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Main;22.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Secondary;17.2
% Companies that consider the following obstacles to the development of biotechnologies as very important: Lack of distribution and marketing channels;Tool required;15.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Total;19.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Main;18.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Secondary;21.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Public acceptance/perception;Tool required;18.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Total;49.8
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Main;54.7
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Secondary;46.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Legal and regulatory requirements;Tool required;43.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Total;59.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Main;66.4
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Secondary;57.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Time/cost;Tool required;48.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Total;22.3
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Main;22.1
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Secondary;20.5
% Companies that consider the following obstacles to the development of biotechnologies as very important: Difficult access to patenting;Tool required;23.7
% Companies with international revenues related to biotechnology activities;Total;23.6
% Companies with international revenues related to biotechnology activities;Main;30.8
% Companies with international revenues related to biotechnology activities;Secondary;19.3
% Companies with international revenues related to biotechnology activities;Tool required;13.3
% Companies representing international revenues related to biotechnology activities;Total;1.5
% Companies representing international revenues related to biotechnology activities;Main;14.7
% Companies representing international revenues related to biotechnology activities;Secondary;0.4
% Companies representing international revenues related to biotechnology activities;Tool required;0.8
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Total;57.6
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Main;64.5
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Secondary;38.7
% International revenues related to biotechnology activities distributed in: Revenues from the EU;Tool required;47.7
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Total;42.4
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Main;35.5
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Secondary;61.3
% International revenues related to biotechnology activities distributed in: Revenues from the rest of the world;Tool required;52.3
% International revenues related to biotechnology activities by classification: International trade in goods and services;Total;82.3
% International revenues related to biotechnology activities by classification: International trade in goods and services;Main;77.1
% International revenues related to biotechnology activities by classification: International trade in goods and services;Secondary;90.6
% International revenues related to biotechnology activities by classification: International trade in goods and services;Tool required;95.7
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Total;14.1
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Main;20.2
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Secondary;0.5
% International revenues related to biotechnology activities by classification: Milestones, royalties, sale or licensing of technologies outside Spain;Tool required;2.3
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Total;1.5
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Main;1.1
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Secondary;3.7
% International revenues related to biotechnology activities by classification: Subsidies from external sources;Tool required;1.0
% International revenues related to biotechnology activities by classification: Other;Total;2.1
% International revenues related to biotechnology activities by classification: Other;Main;1.6
% International revenues related to biotechnology activities by classification: Other;Secondary;5.1
% International revenues related to biotechnology activities by classification: Other;Tool required;1.0